D
David Planchard
Researcher at Institut Gustave Roussy
Publications - 430
Citations - 28831
David Planchard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 55, co-authored 352 publications receiving 19769 citations. Previous affiliations of David Planchard include Université Paris-Saclay & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
TL;DR: Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Journal ArticleDOI
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more
TL;DR: Durvalumab therapy resulted in significantly longer overall survival than placebo, and no new safety signals were identified.
Journal ArticleDOI
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne,James Chih-Hsin Yang,Dong Wan Kim,David Planchard,Yuichiro Ohe,Suresh S. Ramalingam,Myung-Ju Ahn,Sang We Kim,Wu Chou Su,Leora Horn,Daniel Haggstrom,Enriqueta Felip,Joo Hang Kim,Paul Frewer,Mireille Cantarini,Kathryn H. Brown,Paul A. Dickinson,Serban Ghiorghiu,Malcolm R Ranson +18 more
TL;DR: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.
Journal ArticleDOI
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Suresh S. Ramalingam,Johan Vansteenkiste,David Planchard,Byoung Chul Cho,Jhanelle E. Gray,Yuichiro Ohe,Caicun Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,R. Shah,Manuel Cobo,Ki Hyeong Lee,Parneet Cheema,Marcello Tiseo,Thomas John,Meng Chih Lin,Fumio Imamura,Takayasu Kurata,A. Todd,Rachel Hodge,M. Saggese,Yuri Rukazenkov,Jean-Charles Soria,Jean-Charles Soria,Jean-Charles Soria,Flaura Investigators +26 more
TL;DR: Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those whoreceived a comparator EGFR-TKI.